ArticleFrontiers in immunology2026
Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recombinant adeno-associated virus (rAAV)-mediated delivery of neutralizing antibodies is a promising strategy for rapid and durable prophylaxis against SARS-CoV-2. Methods: We evaluated the long-term expression, pharmacokinetics, immunogenicity, biodistribution, and protective efficacy of an rAAV vector of serotype DJ encoding the single-domain antibody P2C5 fused to a human Fc fragment (P2C5-Fc) in mice and common marmosets (Callithrix jacchus). Animals received a single intramuscular administration of rAAV-P2C5-Fc at a dose of 1 × 10¹³ vector genome copies per kg. Results: Rapid antibody detection in serum was observed, reaching peak concentrations (Cmax) by approximately 120 days and remaining at protective levels for >480 days in mice and up to 1,120 days in marmosets. Neutralizing titers closely paralleled serum P2C5-Fc concentrations and provided complete protection against lethal intranasal challenge with SARS-CoV-2 variants B.1.1.1 (Wuhan D614G) and BA.5 (Omicron) even at late time points (216 and 460 days post-administration in mice). Biodistribution analysis showed predominant localization of rAAV at the injection site and regional lymph nodes with minimal off-target spread. Moderate anti-AAV capsid antibody responses were detected, while anti-drug antibodies against P2C5-Fc remained undetectable in both species. Discussion: These findings demonstrate that a single intramuscular injection of rAAV-P2C5-Fc results in rapid onset, sustained expression, and long-term protective efficacy against SARS-CoV-2 variants in two preclinical models, supporting the potential of this platform for durable vectored immunoprophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.